Geron Corporation (GERN)
NASDAQ: GERN · Real-Time Price · USD
1.130
-0.040 (-3.42%)
Jun 8, 2026, 3:33 PM EDT - Market open
Geron Employees
Geron had 258 employees as of December 31, 2025. The number of employees increased by 29 or 12.66% compared to the previous year.
Employees
258
Change (1Y)
29
Growth (1Y)
12.66%
Revenue / Employee
$760,136
Profits / Employee
-$260,880
Market Cap
724.92M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 258 | 29 | 12.66% | 258 | 0 |
| Dec 31, 2024 | 229 | 88 | 62.41% | 229 | 0 |
| Dec 31, 2023 | 141 | 34 | 31.78% | 141 | 0 |
| Dec 31, 2022 | 107 | 35 | 48.61% | 107 | 0 |
| Dec 31, 2021 | 72 | 17 | 30.91% | 69 | 3 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 479 |
| Phathom Pharmaceuticals | 371 |
| Kura Oncology | 260 |
| Omeros | 175 |
| Sana Biotechnology | 142 |
| Aura Biosciences | 113 |
| Janux Therapeutics | 108 |
| ORIC Pharmaceuticals | 104 |
GERN News
- 7 hours ago - Geron Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 7 days ago - Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - GlobeNewsWire
- 19 days ago - Geron Transcript: AGM 2026 - Transcripts
- 19 days ago - Geron Transcript: Stifel 2026 Targeted Oncology Virtual Forum - Transcripts
- 20 days ago - Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - Geron Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 27 days ago - Geron to present RWE study of RYTELO at EHA Congress - TheFly
- 27 days ago - First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026 - GlobeNewsWire